Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer

Marianna Cerasuolo, Federica Maccarinelli, Daniela Coltrini, Ali Mokhtar, Viviana Marolda, Gaia Cristina Ghedini, Sara Rezzola, Arianna Giacomini, Luca Triggiani, Magdalena Kostrzewa, Roberta Verde, Debora Paris, Dominique Melck, Marco Presta, Alessia Ligresti, Roberto Ronca

Research output: Contribution to journalArticlepeer-review

24 Downloads (Pure)

Abstract

Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well as in patients previously exposed to chemotherapy. However, resistance to enzalutamide and enzalutamide withdrawal syndrome have been reported. Thus, reliable and integrated preclinical models are required to elucidate the mechanisms of resistance and to assess therapeutic settings that may delay or prevent the onset of resistance.

In this study, the prostate cancer (PCa) multistage murine model TRAMP and TRAMP-derived cells have been used to extensively characterize in vitro and in vivo the response and resistance to enzalutamide. The therapeutic profile as well as the resistance onset were characterized and a multiscale stochastic mathematical model was proposed to link the in vitro and in vivo evolution of PCa. The model showed that all therapeutic strategies that use enzalutamide result in the onset of resistance. The model also showed that combination therapies can delay the onset of resistance to enzalutamide, and in the best scenario, can eliminate the disease. These results set the basis for the exploitation of this "TRAMP-based platform" to test novel therapeutic approaches and build further mathematical models of combination therapies to treat PCa and CRPC.
Original languageEnglish
Article number0
Pages (from-to)1564-1577
Number of pages14
JournalCancer Research
Volume80
Issue number7
Early online date6 Feb 2020
DOIs
Publication statusPublished - 1 Apr 2020

Fingerprint

Dive into the research topics of 'Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer'. Together they form a unique fingerprint.

Cite this